Searchable abstracts of presentations at key conferences on calcified tissues

ba0004p128 | (1) | ICCBH2015

Patients treated with anti-epileptic drugs have a higher rate of fracture and impaired bone and muscle development compared with controls: results from a pilot study

Simm Peter J , Seah Sebastian , Mackay Mark , Freeman Jeremy , Petty Sandra J , Wark John D

Epilepsy is a relatively common condition of childhood, with anti-epileptic drugs (AEDs) the mainstay of medical therapy. AED use in adults has been shown to be associated with impaired bone density and increased risk of bone fracture. Paediatric data are more limited particularly in relation to fracture risk and skeletal geometry.This study aimed to examine the within-pair differences in fracture prevalence and bone, muscle and balance parameters in sex...

ba0005ni7 | Abstract Presentations | ECTS2016

Exposure to chronic stress induces bone loss via glucocorticoid signalling in osteoblasts

Henneicke Holger , Li Jing-Bao , Gasparini Sylvia J , Seibel Markus J , Zhou Hong

Chronic stress and depression are associated with alterations in the hypothalamic–pituitary–adrenal signalling cascade and considered a risk factor for bone loss and fractures. However, the mechanisms underlying the association between stress and poor bone health are unclear. Utilising a transgenic (tg) mouse model in which glucocorticoid signalling is selectively disrupted in mature osteoblasts and osteocytes (HSD2OB-tg mice), the current study examines t...

ba0005p491 | Steroid hormones and receptors | ECTS2016

Exposure to chronic stress induces bone loss via glucocorticoid signalling in osteoblasts

Henneicke Holger , Li Jing-Bao , Gasparini Sylvia J , Seibel Markus J , Zhou Hong

Chronic stress and depression are associated with alterations in the hypothalamic-pituitary-adrenal signalling cascade and considered a risk factor for bone loss and fractures. However, the mechanisms underlying the association between stress and poor bone health are unclear. Utilising a transgenic (tg) mouse model in which glucocorticoid signalling is selectively disrupted in mature osteoblasts and osteocytes (HSD2OB-tg mice), the current study examines the impact ...

ba0004p195 | (1) | ICCBH2015

Increase of bone mineral density in patients with osteogenesis imperfecta treated with pamidronate disodium.

de Menezes Filho Hamilton Cabral , de Brito Pupo Joyce , de Magalhaes Velasco Bastos Paula , Ae Kim Chong , Bertola Debora Romeo , Ito Simone Sakura , dos Santos Tiago Jeronimo , Setian Nuvarte , Damiani Durval

Objective: This study aimed to evaluate the efficacy of the treatment with pamidronate disodium (PD) with respect to the increase of bone mineral density (BMD) in patients with osteogenesis imperfecta (OI).Patients and methods: We evaluated nine patients (six boys) with OI (four with type III, four with type IV, one with type I) treated with PD from 4.68 to 7.92 years (mean±S.D.: 6.75±1.38 years). Intravenous PD was administered ...

ba0002p185 | (1) | ICCBH2013

An unusual presentation of progressive osseous heteroplasia in a 7-year-old female child

Schrander D E , Welting T J , Schrander J J P , van Rhijn L W , Korver-Keularts I , Schrander-Stumpel C T R M

Background: Progressive osseous heteroplasia (POH) (OMIM 166350) is a rare autosomal dominant condition, characterized by heterotopic ossification of the skin, subcutaneous fat and deep connective tissue. This condition is distinct from Albright’s hereditary osteodystrophy or Mccune–Albright syndrome (AHO) (OMIM 103580) and fibrodysplasia ossificans progressiva (FOP) (OMIM 135100).Presenting problem: We present an unu...

ba0001pp446 | Osteoporosis: treatment | ECTS2013

Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate– a randomized placebo-controlled trial

Chapurlat Roland , De Villiers Tobias , Bonnick Sydney , Odio Alberto , Palacios Santiago , Scott Boyd , De Tilleghem Celine Le Bailly , DaSilva Carolyn , Leung Albert , Gurner Deborah

Odanacatib (ODN) is an orally-active cathepsin K inhibitor being developed for the treatment of postmenopausal osteoporosis. This study evaluated the effects of ODN 50mg once weekly on BMD, bone turnover markers and safety in patients previously treated with alendronate (ALN).This was a randomized, double-blind, placebo-controlled, 24-month study. The primary endpoint was % change from baseline at month 24 of femoral neck (FN) BMD. Postmenopausal women (...

ba0002p102 | (1) | ICCBH2013

Influence of nutritional status in the bone mass assessed by quantitative ultrasonography of boys

de Oliveira Barbeta Vinicius Justino , Bertapelli Fabio , Goncalves Ezequiel Moreira , Krahenbuhl Tathyane , de Barros Ramalho Luiz Carlos , Martin Juan Eduardo Samur-San , Ribeiro Roberto Regis , Guerra-Junior Gil

The childhood is an important period for bone mass acquisition, and this tissue may be influenced by the nutritional status. However, the relation between the nutritional status and the bone parameters of quantitative ultrasound (QUS) remains unclear. The aim of this study was to verify the influence of nutritional status on bone mass assessed by QUS in male children from 7 to 10 years old. The sample consisted of 461 Brazilians pre-pubertal schoolchildren (8.30±1.13 year...

ba0005oc3.1 | Clinical trials, FGF-23 and focal osteoporosis | ECTS2016

Effect of odanacatib on bone density and estimated bone strength in postmenopausal women: a CT-based sub-study of the phase 3 long-term odanacatib fracture trial (LOFT)

Langdahl Bente , De Villiers Tobias , Keaveny Tony M , Engelke Klaus , Genant Harry , Ather Shabana , Giezek Hilde , Lombardi Antonio , Leung Albert , de Papp Anne

Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. In the Phase 3, Long-Term ODN Fracture Trial (LOFT; NCT00529373), ODN significantly reduced fracture risk. This imaging sub-study primarily investigated the effect of ODN on volumetric BMD (vBMD) of the lumbar spine (LS) and total hip (TH) using quantitative computed tomography (QCT).Women aged ≥65 without baseline radiographic vertebra...